Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NY-ESO-1 TCR-T cell therapy - Tmunity Therapeutics

Next Previous
Drug Profile

NY-ESO-1 TCR-T cell therapy - Tmunity Therapeutics

Alternative Names: NY-ESO-1 TCR-T triple knockout TCR therapy; NY-ESO-1-redirected CRISPR edited T cells; NYCE T Cells

Latest Information Update: 26 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tmunity Therapeutics
  • Developer Parker Hughes Institute; Tmunity Therapeutics; University of Pennsylvania
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma; Multiple myeloma; Myxoid liposarcoma; Synovial sarcoma

Most Recent Events

  • 22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
  • 07 May 2020 Discontinued - Phase-I for Malignant melanoma (Second-line therapy or greater) in USA (Parenteral), since the sponsor intends to pursue other targets (NCT03399448)
  • 07 May 2020 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (Parenteral), since the sponsor intends to pursue other targets (NCT03399448)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top